Gujarat Themis Biosyn LtdQ1 FY27
Gujarat Themis Biosyn Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹410P/E: 85.3Market Cap: ₹4.2K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →GTBL aims to grow its top line on a high-teen percentage basis over the next 3 to 5 years.
- →With expanded capacity investments, the company expects increasing asset turns and quarter-on-quarter growth in revenues.
- →The integration of recent acquisitions like MicroBiopharm and Sanofi’s portfolio is expected to add significant top-line and earnings growth.
- →MicroBiopharm acquisition will enable GTBL to enter higher value fermentation-based CDMO space, expanding capabilities in immunosuppressants, oncology, peptides, plasmids, precision fermentation, enzyme engineering, and ADCs.
- →Sanofi portfolio acquisition secures existing bread-and-butter APIs and opens up formulations, improving margin and revenue through better distribution and integration of API production.
- →Overall, GTBL is focused on transforming into a fermentation-led integrated pharmaceutical company to participate in higher-value opportunities.
- →The company expects some synergy-related projects and revenue growth to start within the first year of acquisitions integration.
Margin guidance
Category 3- →FY26 revenue and profitability remained stable and in line with previous years, despite some production challenges.
- →GTBL was sold out in capacity, limiting growth; however, recent investments in fermentation and API facilities are expected to drive future growth.
- →Management aims for high-teen percentage growth annually over the next 3-5 years.
- →New acquisitions (MicroBiopharm and Sanofi brands) expected to add to revenues and earnings after integration and stabilization.
- →Synergies from acquisitions anticipated to start within the first year and contribute significantly.
- →EBITDA margins expected to be maintained close to current levels post-integration.
- →Focus on transforming GTBL into a fermentation-based CDMO with broader capabilities to capture higher-value opportunities.
- →Raising equity (~INR 1,000 crores) and debt (~INR 2,000 crores) planned to support growth.
- →Long-term vision includes diversified, innovation-led growth driving sustainable earnings expansion.
Fundraise plans
Yes- →Gujarat Themis Biosyn Limited is planning fundraising activities involving both debt and equity.
- →They are currently preparing for multiple avenues in terms of funding to finalize an optimal mix of debt and equity.
- →The company aims to raise up to INR 1,000 crores through equity as of now.
- →Debt raise amount is yet to be decided; options remain open and will be finalized at the appropriate time.
- →The company has recently taken an extra INR 450 crores debt flexibility option plus INR 1,000 crores guarantee from a group company to support funding needs.
- →Most of the capex is completed; for FY27, expected capex on the base business is around INR 20 crores including maintenance.
- →Funding is largely secured for the MicroBiopharm Japan deal, with some last-minute approvals pending.
Order book
- There is no explicit mention of the current or expected order book or pending orders in the transcript.
- However, Sachin Patel mentioned consistently being sold out in terms of capacity over the past few years, implying strong demand.
- The company has seen robust increase in sales volumes and a healthy demand outlook for products as per Q1 FY27 performance.
- Integration of recent acquisitions like MicroBiopharm and Sanofi portfolio is expected to lead to new projects and add to revenues.
- Some projects from acquisitions are expected to start within the first year, suggesting a growing pipeline.
- Management highlighted the readiness to execute expansion projects and integrate acquisitions to broaden product portfolio and capabilities.
Summary: While exact order book figures are not provided, the company is operating at full capacity with increased demand and new projects from acquisitions expected to contribute soon.
Capex plans
Yes- →Most of the capex is already completed by the company with only INR10-15 crores left for last mile completion in FY27, along with some maintenance capex totaling around INR20 crores for the year. (Page 11)
- →Over the last 3 years, incremental investment of around INR370 crores in gross block, including new fermentation facility, API facility, new R&D infrastructure, and hybrid power project. (Page 12)
- →Focus on expansion projects execution and integrating recent acquisitions to commercialize new capabilities, broaden product portfolio while maintaining strong financial performance. (Page 19)
- →Additional fermentation capacity expansion (practically doubled capacity), fully operational by end of August 2026, enabling increase in API manufacturing capabilities. (Page 9)
- →Planning fundraising of up to INR1,000 crores through equity and managing debt levels optimally for acquisitions. (Page 10)
- →Long-term vision to grow on a high-teen basis over 3-5 years driven by organic growth and acquisitions with fermentation-based CDMO transformation focus. (Page 12)
Track Gujarat Themis Biosyn Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- →FY26 revenue and profitability remained stable and in line with previous years, despite some production challenges.
- →GTBL was sold out in capacity, limiting growth; however, recent investments in fermentation and API facilities are expected to drive future growth.
- →Management aims for high-teen percentage growth annually over the next 3-5 years.
- →New acquisitions (MicroBiopharm and Sanofi brands) expected to add to revenues and earnings after integration and stabilization.
- →Synergies from acquisitions anticipated to start within the first year and contribute significantly.
- →EBITDA margins expected to be maintained close to current levels post-integration.
- →Focus on transforming GTBL into a fermentation-based CDMO with broader capabilities to capture higher-value opportunities.
- →Raising equity (~INR 1,000 crores) and debt (~INR 2,000 crores) planned to support growth.
- →Long-term vision includes diversified, innovation-led growth driving sustainable earnings expansion.
Order book
- There is no explicit mention of the current or expected order book or pending orders in the transcript.
- However, Sachin Patel mentioned consistently being sold out in terms of capacity over the past few years, implying strong demand.
- The company has seen robust increase in sales volumes and a healthy demand outlook for products as per Q1 FY27 performance.
- Integration of recent acquisitions like MicroBiopharm and Sanofi portfolio is expected to lead to new projects and add to revenues.
- Some projects from acquisitions are expected to start within the first year, suggesting a growing pipeline.
- Management highlighted the readiness to execute expansion projects and integrate acquisitions to broaden product portfolio and capabilities.
Summary: While exact order book figures are not provided, the company is operating at full capacity with increased demand and new projects from acquisitions expected to contribute soon.
How does Gujarat Themis Biosyn Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Gujarat Themis Biosyn Ltd
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Gujarat Themis Biosyn Ltd rank in Pharmaceuticals & Biotechnology?
Compare Gujarat Themis Biosyn Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.